Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration

Canadian Journal of Ophthalmology

Volumn 47, Issue 2, 2012, Pages 159-164

  Kent, Jerrod S ^a   Iordanous, Yiannis ^a   Mao, Alex ^a   Powell, Anne Marie ^a   Kent, Shefalee Shukla ^a   Sheidow, Tom G ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; CANADA; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETINA MACULA AGE RELATED DEGENERATION; VISUAL ACUITY;

EID: 84862295352     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2012.01.003     Document Type: Review

References (14)

1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1992;99:933-43.
2. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25:111-8. (Pubitemid 40365933)
3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-44. (Pubitemid 44511558)
4. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-31. (Pubitemid 44511557)
5. Steinbrook R. The price of sight - ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355:1409-12. (Pubitemid 44511554)
6. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year. Am J Ophthalmol. 2008; 145:239-48.
7. Antoszyk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008;145: 862-74.
8. Durbin M, Abunto T, Chang M, Lujan B. Retinal measurements: comparison between Cirrus HD-OCT and Stratus OCT. Carl Zeiss Meditec, Inc. Company product information. 2007. Available at http://www.zeiss.com/C125679E00525939/ EmbedTitelIntern/Cirrus WhitePaper/$File/Cirrus-WhitePaper.pdf. Accessed January 28, 2010.
9. Chang TS, Kokame G, Casey R, et al. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration. Retina. 2009;29: 1235-41.
10. Stepien KE, Rosenfeld PJ, Puliafito CA, et al. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2009;29:1067-73.
11. Ehlers JP, Spirn MJ, Shah CP, et al. Ranibizumab for exudative agerelated macular degeneration in eyes previously treated with alternative vascular endothelial growth factor inhibitors. Ophthalmic Surg Lasers Imaging. 2010;41:182-9.
12. Karagiannis DA, Ladas ID, Parikakis E, et al. Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe? Clin Interv Aging. 2009;4:457-61.
13. The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New Engl J Med. 2011;364: 1897-908.
14. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65.e5.